PRP Therapy

  • Ibrahim Fatih CengizEmail author
  • J. Miguel Oliveira
  • Rui L. Reis
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1059)


Osteochondral lesions remain as a clinical challenge despite the advances in orthopedic regenerative strategies. Biologics, in particular, platelet-rich plasma, has been applied for the reparative and regenerative effect in many tissues, and osteochondral tissue is not an exception. Platelet-rich plasma is an autologous concentrate prepared from the collected blood; thus, this safe application is free of immune response or risk of transmission of disease. It has a high potential to promote regeneration, thanks to its content, and can be applied alone or can reinforce a tissue engineering strategy. The relevant works making use of platelet-rich plasma in osteochondral lesions are overviewed herein. The practical success of platelet-rich plasma is uncertain since there are many factors involved including but not limited to its preparation and administration method. Nevertheless, today, the issues and challenges of platelet-rich plasma have been well acknowledged by researchers and clinicians. Thus, it is believed that a consensus will be built it, and then with high-quality randomized controlled trials and standardized protocols, the efficacy of platelet-rich plasma therapy can be better evaluated.


  • The need of treating the osteochondral lesions has not been yet met in the clinics.

  • Thanks to being an autologous source of growth factors, interleukins, and other cytokines and relative ease of clinical application, i.e., during a single-step surgical procedure, the use of platelet-rich plasma is of great interest.

  • The high theoretical potential of the role of platelet-rich plasma in the regeneration process of osteochondral lesions is known, and the efficiency needs to be confirmed by high-quality randomized controlled trials for a robust position in the treatments of osteochondral lesions in the clinics.


Platelet-rich plasma Osteochondral  Regeneration Tissue engineering 



This work is a result of the project FROnTHERA (NORTE-01-0145-FEDER-000023), supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). IFC thanks the Portuguese Foundation for Science and Technology (FCT) for the PhD scholarship (SFRH/BD/99555/2014). JMO also thanks the FCT for the funds provided under the program Investigador FCT 2012 and 2015 (IF/00423/2012 and IF/01285/2015).


  1. 1.
    Dhillon MS, Patel S, John R (2017) PRP in OA knee–update, current confusions and future options. SICOT J 3:27CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Andia I, Abate M (2017) Platelet-rich plasma: combinational treatment modalities for musculoskeletal conditions. Front Med:1–14. DOI: 10.1007/s11684-017-0551-6 CrossRefPubMedGoogle Scholar
  3. 3.
    Nguyen RT, Borg-Stein J, McInnis K (2011) Applications of platelet-rich plasma in musculoskeletal and sports medicine: an evidence-based approach. PM R 3(3):226–250CrossRefPubMedGoogle Scholar
  4. 4.
    Engebretsen L, Steffen K, Alsousou J, Anitua E, Bachl N, Devilee R, Everts P, Hamilton B, Huard J, Jenoure P (2010) IOC consensus paper on the use of platelet-rich plasma in sports medicine. Br J Sports Med 44(15):1072–1081CrossRefPubMedGoogle Scholar
  5. 5.
    Qureshi AH, Chaoji V, Maiguel D, Faridi MH, Barth CJ, Salem SM, Singhal M, Stoub D, Krastins B, Ogihara M (2009) Proteomic and phospho-proteomic profile of human platelets in basal, resting state: insights into integrin signaling. PLoS One 4(10):e7627CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Everts PA, Knape JT, Weibrich G, Schonberger J, Hoffmann J, Overdevest EP, Box HA, van Zundert A (2006) Platelet-rich plasma and platelet gel: a review. Journal of ExtraCorporeal. Technology 38(2):174Google Scholar
  7. 7.
    Marx RE (2001) Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent 10(4):225–228CrossRefPubMedGoogle Scholar
  8. 8.
    Marx RE (2004) Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 62:489–496CrossRefPubMedGoogle Scholar
  9. 9.
    Pietrzak WS, Eppley BL (2005) Platelet rich plasma: biology and new technology. J Craniofac Surg 16(6):1043–1054CrossRefPubMedGoogle Scholar
  10. 10.
    Andia I, Maffulli N (2013) Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol 9(12):721–730CrossRefPubMedGoogle Scholar
  11. 11.
    Cengiz IF, Oliveira JM, Ochi M, Nakamae A, Adachi N, Reis RL (2017) “Biologic” treatment for meniscal repair. In: Injuries and health problems in football. Springer. Berlin, Heidelberg. 679–686CrossRefGoogle Scholar
  12. 12.
    Piuzzi NS, Chughtai M, Khlopas A, Harwin SF, Miniaci A, Mont MA, Muschler GF (2017) Platelet-rich plasma for the treatment of knee osteoarthritis: a review. J Knee Surg 30(07):627–633CrossRefPubMedGoogle Scholar
  13. 13.
    Utku B, Dönmez G, Büyükdoğan K, Karanfil Y, Tolevska RD, Korkusuz F, Doral MN (2015) Platelet-rich plasma: from laboratory to the clinic. Sports injuries: prevention, diagnosis, treatment and. Rehabilitation:3223–3250CrossRefGoogle Scholar
  14. 14.
    Araki J, Jona M, Eto H, Aoi N, Kato H, Suga H, Doi K, Yatomi Y, Yoshimura K (2011) Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: maximization of platelet concentration and removal of fibrinogen. Tissue Eng Part C Methods 18(3):176–185CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cavallo C, Roffi A, Grigolo B, Mariani E, Pratelli L, Merli G, Kon E, Marcacci M, Filardo G (2016) Platelet-rich plasma: the choice of activation method affects the release of bioactive molecules. Biomed Res Int 2016:1CrossRefGoogle Scholar
  16. 16.
    Chahla J, Cinque ME, Piuzzi NS, Mannava S, Geeslin AG, Murray IR, Dornan GJ, Muschler GF, LaPrade RF (2017) A call for standardization in platelet-rich plasma preparation protocols and composition reporting: a systematic review of the clinical orthopaedic literature. JBJS 99(20):1769–1779CrossRefGoogle Scholar
  17. 17.
    Navani A, Li G, Chrystal J (2017) Platelet rich plasma in musculoskeletal pathology: a necessary rescue or a lost cause? Pain Physician 20(3):E345PubMedGoogle Scholar
  18. 18.
    Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA (2009) Platelet-rich plasma from basic science to clinical applications. Am J Sports Med 37(11):2259–2272CrossRefPubMedGoogle Scholar
  19. 19.
    Castillo TN, Pouliot MA, Kim HJ, Dragoo JL (2011) Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med 39(2):266–271CrossRefPubMedGoogle Scholar
  20. 20.
    Ehrenfest DMD, Rasmusson L, Albrektsson T (2009) Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF). Trends Biotechnol 27(3):158–167CrossRefGoogle Scholar
  21. 21.
    Riboh JC, Saltzman BM, Yanke AB, Fortier L, Cole BJ (2016) Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. Am J Sports Med 44(3):792–800CrossRefPubMedGoogle Scholar
  22. 22.
    Fréchette J-P, Martineau I, Gagnon G (2005) Platelet-rich plasmas: growth factor content and roles in wound healing. J Dent Res 84(5):434–439CrossRefPubMedGoogle Scholar
  23. 23.
    Cengiz IF, Oliveira JM, Reis RL (2014) Tissue engineering and regenerative medicine strategies for the treatment of osteochondral lesions. In: 3D multiscale physiological human. Springer, London pp 25–47Google Scholar
  24. 24.
    Yan L-P, Oliveira JM, Oliveira AL, Reis RL (2015) Current concepts and challenges in osteochondral tissue engineering and regenerative medicine. ACS Biomater Sci Eng 1(4):183–200CrossRefGoogle Scholar
  25. 25.
    Scioli MG, Bielli A, Gentile P, Cervelli V, Orlandi A (2017) Combined treatment with platelet-rich plasma and insulin favours chondrogenic and osteogenic differentiation of human adipose-derived stem cells in three-dimensional collagen scaffolds. J Tissue Eng Regen Med 11(8):2398–2410CrossRefPubMedGoogle Scholar
  26. 26.
    Marmotti A, Bruzzone M, Bonasia D, Castoldi F, Rossi R, Piras L, Maiello A, Realmuto C, Peretti G (2012) One-step osteochondral repair with cartilage fragments in a composite scaffold. Knee Surg Sports Traumatol Arthrosc 20(12):2590–2601CrossRefPubMedGoogle Scholar
  27. 27.
    Lee J-C, Min HJ, Park HJ, Lee S, Seong SC, Lee MC (2013) Synovial membrane–derived mesenchymal stem cells supported by platelet-rich plasma can repair osteochondral defects in a rabbit model. Arthroscopy: The Journal of Arthroscopic & Related Surgery 29(6):1034–1046CrossRefGoogle Scholar
  28. 28.
    Smyth NA, Haleem AM, Ross KA, Hannon CP, Murawski CD, Do HT, Kennedy JG (2016) Platelet-rich plasma may improve osteochondral donor site healing in a rabbit model. Cartilage 7(1):104–111CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Altan E, Aydin K, Erkocak O, Senaran H, Ugras S (2014) The effect of platelet-rich plasma on osteochondral defects treated with mosaicplasty. Int Orthop 38(6):1321–1328CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Gormeli G, Karakaplan M, Gormeli CA, Sarikaya B, Elmali N, Ersoy Y (2015) Clinical effects of platelet-rich plasma and hyaluronic acid as an additional therapy for talar osteochondral lesions treated with microfracture surgery: a prospective randomized clinical trial. Foot Ankle Int 36(8):891–900CrossRefPubMedGoogle Scholar
  31. 31.
    Guney A, Akar M, Karaman I, Oner M, Guney B (2015) Clinical outcomes of platelet rich plasma (PRP) as an adjunct to microfracture surgery in osteochondral lesions of the talus. Knee Surg Sports Traumatol Arthrosc 23(8):2384–2389CrossRefPubMedGoogle Scholar
  32. 32.
    Guney A, Yurdakul E, Karaman I, Bilal O, Kafadar IH, Oner M (2016) Medium-term outcomes of mosaicplasty versus arthroscopic microfracture with or without platelet-rich plasma in the treatment of osteochondral lesions of the talus. Knee Surg Sports Traumatol Arthrosc 24(4):1293–1298CrossRefPubMedGoogle Scholar
  33. 33.
    J-p S, Tanabe T, Tsuzuki N, Haneda S, Yamada K, Furuoka H, Tabata Y, Sasaki N (2013) Effects of bilayer gelatin/β-tricalcium phosphate sponges loaded with mesenchymal stem cells, chondrocytes, bone morphogenetic protein-2, and platelet rich plasma on osteochondral defects of the talus in horses. Res Vet Sci 95(3):1210–1216CrossRefGoogle Scholar
  34. 34.
    J-p S, Kambayashi Y, Itho M, Haneda S, Yamada K, Furuoka H, Tabata Y, Sasaki N (2015) Effects of a synovial flap and gelatin/β-tricalcium phosphate sponges loaded with mesenchymal stem cells, bone morphogenetic protein-2, and platelet rich plasma on equine osteochondral defects. Res Vet Sci 101:140–143CrossRefGoogle Scholar
  35. 35.
    Smyth NA, Haleem AM, Murawski CD, Do HT, Deland JT, Kennedy JG (2013) The effect of platelet-rich plasma on autologous osteochondral transplantation: an in vivo rabbit model. JBJS 95(24):2185–2193CrossRefGoogle Scholar
  36. 36.
    Betsch M, Schneppendahl J, Thuns S, Herten M, Sager M, Jungbluth P, Hakimi M, Wild M (2013) Bone marrow aspiration concentrate and platelet rich plasma for osteochondral repair in a porcine osteochondral defect model. PLoS One 8(8):e71602CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Sun Y, Feng Y, Zhang C, Chen S, Cheng X (2010) The regenerative effect of platelet-rich plasma on healing in large osteochondral defects. Int Orthop 34(4):589–597CrossRefPubMedGoogle Scholar
  38. 38.
    Kon E, Filardo G, Delcogliano M, Fini M, Salamanna F, Giavaresi G, Martin I, Marcacci M (2010) Platelet autologous growth factors decrease the osteochondral regeneration capability of a collagen-hydroxyapatite scaffold in a sheep model. BMC Musculoskelet Disord 11(1):220CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    van Bergen CJ, Kerkhoffs GM, Özdemir M, Korstjens CM, Everts V, van Ruijven LJ, van Dijk CN, Blankevoort L (2013) Demineralized bone matrix and platelet-rich plasma do not improve healing of osteochondral defects of the talus: an experimental goat study. Osteoarthr Cartil 21(11):1746–1754CrossRefPubMedGoogle Scholar
  40. 40.
    Xie X, Wang Y, Zhao C, Guo S, Liu S, Jia W, Tuan RS, Zhang C (2012) Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration. Biomaterials 33(29):7008–7018CrossRefPubMedGoogle Scholar
  41. 41.
    Krych AJ, Nawabi DH, Farshad-Amacker NA, Jones KJ, Maak TG, Potter HG, Williams RJ III (2016) Bone marrow concentrate improves early cartilage phase maturation of a scaffold plug in the knee: a comparative magnetic resonance imaging analysis to platelet-rich plasma and control. Am J Sports Med 44(1):91–98CrossRefPubMedGoogle Scholar
  42. 42.
    Gu W, Li T, Shi Z, Mei G, Xue J, Zou J, Wang X, Zhang H, Xu H (2017) Management of Hepple stage V osteochondral lesion of the talus with a platelet-rich plasma scaffold. Biomed Res Int 2017:1Google Scholar
  43. 43.
    Mei-Dan O, Carmont MR, Laver L, Mann G, Maffulli N, Nyska M (2012) Platelet-rich plasma or hyaluronate in the management of osteochondral lesions of the talus. Am J Sports Med 40(3):534–541CrossRefPubMedGoogle Scholar
  44. 44.
    Metcalf KB, Mandelbaum BR, McIlwraith CW (2013) Application of platelet-rich plasma to disorders of the knee joint. Cartilage 4(4):295–312CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Sheth U, Simunovic N, Klein G, Fu F, Einhorn TA, Schemitsch E, Ayeni OR, Bhandari M (2012) Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis. J Bone Joint Surg 94(4):298–307CrossRefPubMedGoogle Scholar
  46. 46.
    Nourissat G, Mainard D, Kelberine F, French Arthroscopic Society (SFA) (2013) Current concept for the use of PRP in arthroscopic surgery. Orthop Traumatol Surg Res 99(8):S407–S410CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ibrahim Fatih Cengiz
    • 1
    • 2
    Email author
  • J. Miguel Oliveira
    • 1
    • 2
    • 3
  • Rui L. Reis
    • 1
    • 2
    • 3
  1. 1.3B’s Research Group–Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative MedicineBarco, GuimarãesPortugal
  2. 2.ICVS/3B’s–PT Government Associate LaboratoryBraga/GuimarãesPortugal
  3. 3.The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of MinhoBarco/GuimarãesPortugal

Personalised recommendations